Using the same cohort of patients (TCGA), we assessed the correlation of IgSF11 expression with three critical immune checkpoints, PDL-1 and PD-1 (both known to present high levels of expression in advanced glioma grades) (23–25) and VISTA, which is known as IgSF11 receptor (20). Here, IGSF11 is linked to central nervous system cancer.